Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VQW
|
|||
| Former ID |
DNC001271
|
|||
| Drug Name |
Sant7
|
|||
| Synonyms |
beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Investigative | [1] | |
| Company |
Sigma-Tau
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27N7O13P2S
|
|||
| Canonical SMILES |
C1=C(N=C(S1)C2C(C(C(O2)COP(=O)(CP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)O)C(=O)N
|
|||
| InChI |
1S/C20H27N7O13P2S/c21-16-10-18(24-4-23-16)27(5-25-10)20-14(31)12(29)9(40-20)2-38-42(35,36)6-41(33,34)37-1-8-11(28)13(30)15(39-8)19-26-7(3-43-19)17(22)32/h3-5,8-9,11-15,20,28-31H,1-2,6H2,(H2,22,32)(H,33,34)(H,35,36)(H2,21,23,24)/t8-,9-,11-,12-,13-,14-,15-,20-/m1/s1
|
|||
| InChIKey |
CRWWKLKZKYLFQV-HVIRUEHBSA-N
|
|||
| CAS Number |
CAS 102977-57-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 6 receptor (IL6R) | Target Info | Antagonist | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Reactome | MAPK3 (ERK1) activation | |||
| MAPK1 (ERK2) activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Senescence and Autophagy in Cancer | ||||
| IL-6 signaling pathway | ||||
| Differentiation Pathway | ||||
| Interleukin-6 signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.